In recent years, the integration of immunotherapy in the treatment of lung cancer has marked a significant evolution in the field. This is evidenced by the surge in the volume of scientific publications, reflecting rapid advances over time. This paper presents a bibliometric analysis of lung cancer and immunotherapy research from January 2012 to December 2022, drawing on the Web of Science literature database and using the citexs data analysis platform to examine the shifts in topic hotspots over the decade. A total of 8,722 publications were retrieved, with annual publication numbers soaring from 79 in 2012 to 2,112 in 2021. The most prolific country in terms of publication volume was China (n = 3,363, 38.56%), with The University of Texas MD Anderson Cancer Center making the most significant institutional contribution (n = 156, 1.79%). Notably, the most productive authors in this domain were Benjamin Besse and Marina Chiara Garassino, who have collectively published 35 articles to date. Predominant research themes include PD1/PDL1, clinical trials, pembrolizumab, nivolumab, and immune checkpoint inhibitors. Moreover, this paper visualizes the analysis of journals, keywords, key genes and targets, and associated diseases, aiming to provide a systematic review and a forward-looking perspective on research in lung cancer and immunotherapy. By exploring current research dynamics and hotspots and identifying areas for improvement, this study seeks to provide valuable insights for future investigations in this burgeoning field.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586257 | PMC |
http://dx.doi.org/10.3389/fonc.2024.1428307 | DOI Listing |
J Cancer Res Ther
December 2024
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong, China.
Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has revolutionized one of the standard most efficient treatments for EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently one of most efficient treatments in clinical practice. However, it has a potentially fatal side effect: interstitial lung disease (ILD).
View Article and Find Full Text PDFJ Cancer Res Ther
December 2024
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, P.R. China.
Background: Cryoablation induces antitumor immune responses. Spatial transcriptomic landscape technology has been used to determine the micron-level panoramic transcriptomics of tissue slices in situ.
Methods: The effects of cryoablation on the immune microenvironment in non-small cell lung cancer (NSCLC) were explored by comparing the Whole Transcriptome Atlas (WTA) panel of immune cells before and after cryoablation using the spatial transcriptomic landscape.
J Cancer Res Ther
December 2024
Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China.
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare lung cancer characterized by early metastasis and invasion. It is predominantly diagnosed at a locally advanced or metastatic stage, hindering the possibility of surgical intervention. However, a standard treatment for advanced PSC remains unestablished.
View Article and Find Full Text PDFJ Cancer Res Ther
December 2024
No. 2 Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Objective: This retrospective study aimed to determine the need for lymph node resection during surgical treatment in patients with stage IA non-small-cell lung cancer (NSCLC).
Materials And Methods: A total of 1428 patients diagnosed with cT1N0M0 1 A stage NSCLC who underwent surgery were divided into two groups: lymphadenectomy (n = 1324) and nonlymphadenectomy (n = 104). The effects of lymph node resection on overall survival (OS) and recurrence-free survival (RFS) and on clinicopathological factors that affected the prognosis of the patients were investigated.
J Cancer Res Ther
December 2024
Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. The mechanisms underlying metastasis, which contributes to poor outcomes, remain elusive.
Methods: We used the Cancer Genome Atlas dataset to compare mRNA expression patterns of integrin α6 (ITGA6) and integrin β4 (ITGB4) in patients with CRC.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!